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Abstract
Background: 18F-FLT is a novel PET radiotracer which has demonstrated a strong potential utility
for imaging cellular proliferation in human tumors in vivo. To facilitate future regulatory approval
of 18F-FLT for clinical use, we wished to demonstrate the safety of radiotracer doses of 18F-FLT
administered to human subjects, by: 1) performing an evaluation of the toxicity of 18F-FLT
administered in radiotracer amounts for PET imaging, 2) comparing a radiotracer dose of FLT to
clinical trial doses of FLT.
Methods: Twenty patients gave consent to a 18F-FLT injection, subsequent PET imaging, and blood
draws. For each patient, blood samples were collected at multiple times before and after 18F-FLT
PET. These samples were assayed for a comprehensive metabolic panel, total bilirubin, complete
blood and platelet counts. 18F-FLT doses of 2.59 MBq/Kg with a maximal dose of 185 MBq (5 mCi)
were used. Blood time-activity curves were generated for each patient from dynamic PET data,
providing a measure of the area under the FLT concentration curve for 12 hours (AUC12).
Results: No side effects were reported. Only albumin, red blood cell count, hematocrit and
hemoglobin showed a statistically significant decrease over time. These changes are attributed to
IV hydration during PET imaging and to subsequent blood loss at surgery. The AUC12 values
estimated from imaging data are not significantly different from those found from serial measures
of FLT blood concentrations (p = 0.66). The blood samples-derived AUC12 values range from 0.232
ng*h/mL to 1.339 ng*h/mL with a mean of 0.802 ± 0.303 ng*h/mL. This corresponds to 0.46% to
2.68% of the lowest and least toxic clinical trial AUC12 of 50 ng*h/mL reported by Flexner et al
(1994). This single injection also corresponds to a nearly 3,000-fold lower cumulative dose than in
Flexner's twice daily trial.
Conclusion: This study shows no evidence of toxicity or complications attributable to 18F-FLT
injected intravenously.
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Background
3'-Deoxy-3'-[18F]fluorothymidine (18F-FLT) is a new tracer
for positron emission tomography (PET) being evaluated
at several centers across the United States and worldwide.
The interest generated by FLT as a radiotracer stems from
its potential as a proliferation tracer that would accumu-
late in tumors in proportion to their growth rate.
FLT, a thymidine nucleoside analog, undergoes the same
first metabolic step as thymidine when it is 5'-monophos-
phorylated by the cytosolic enzyme thymidine kinase-1
(TK-1), however, the 3' substitution prevents further
incorporation into DNA. TK-1 is an enzyme within the
pyrimidine nucleoside salvage pathway and is up-regu-
lated just prior to and during the DNA synthesis phase of
the cell cycle [1-6]. Consequently, TK-1 is closely associ-
ated with DNA synthesis and is significantly increased in
rapidly proliferating cells and therefore is over-expressed
in many tumors. These characteristics led to the evalua-
tion of 18F-FLT as a tumor-imaging agent for PET. Grierson
and Shields first developed 18F-FLT as a potential PET
imaging agent [7,8]. 18F-FLT has since been demonstrated
as a proliferation tracer in tumor cell cultures [9,10] as
well as in human lung lesions imaged by PET [11-13]. The
potential impact of 18F-FLT on tumor imaging is two-fold:
first, tumor proliferation is a prognostic factor for certain
tumor types (e.g. non-small cell lung cancer [14]) and 18F-
FLT PET imaging could help refine the prognostic evalua-
tion of these tumors; second, a hallmark of tumors having
responded to therapy is a loss of the ability for sustained
proliferation. Hence, 18F-FLT PET imaging may prove use-
ful in assessing tumor response to therapy.
As a proliferation tracer for PET imaging, 18F-FLT is gener-
ating much interest but its widespread use will first require
an evaluation of its safety when administered in tracer
quantities. We have previously reported the dosimetry for
18F-FLT, providing radiation dose estimates for human use
[15]. A study of the toxicity of 18F-FLT administered in
tracer quantities for PET has not been reported yet.
FLT was initially investigated as a treatment for HIV infec-
tion in humans [16]. Two clinical trials of FLT adminis-
tered in therapeutic doses revealed evidence of
hematologic and hepatic toxicity as well as peripheral
neuropathy [17]. The lowest regimen tested was 50 ng*h/
mL for a 12 hour dosing interval over 112 days and led to
only mild neuropathy within 40 days of therapy. The pur-
pose of this study is to perform an evaluation of the toxic-
ity of 18F-FLT administered in radiotracer amounts for PET
imaging and to compare such a radiotracer dose of 18F-FLT
to therapeutic doses previously tested in clinical trials.
Methods
Patient selection
This evaluation was conducted as part of a University of
Washington IRB approved study of 18F-FLT PET in non-
small cell lung cancer (NSCLC). All patients were referred
with a proven or suspected diagnosis of NSCLC to the
University of Washington Medical Center or the Veterans
Affairs Puget Sound Health Care System between March
2000 and April 2002. Twenty patients (12 men, 8
women) gave written informed consent to the 18F-FLT
injection, subsequent PET imaging, and blood draws. The
age range for males was 45–81 years (mean 66.6 years)
and for females was 46–75 years (mean 60 years). The
weight range for males was 54–126 Kg (mean 81.6 Kg)
and for females was 46–113 Kg (mean 73.4 Kg). All
female subjects were post-menopausal.
Patient preparation
Study participants had no history of abnormal renal,
hepatic or hematologic function. No dietary preparation
was required from the patient prior to 18F-FLT administra-
tion. An intravenous (IV) catheter was placed in each of
the patient's arms, the first one for 18F-FLT injection and
the other to collect blood samples. In eight cases an arte-
rial catheter was used for blood sampling. Patients were
hydrated with 500 mL of IV normal saline during the
course of the PET imaging procedure.
18F-FLT synthesis
18F-FLT was synthesized according to the method devel-
oped by Grierson et al. [7,8] with a minimum acceptable
specific activity of 0.1 Ci/μmol. Specific activity was deter-
mined by measuring UV absorbance at 266 nm correlated
with a radioactivity measurement. The specific activity of
FLT was governed by the amount of radioactivity used for
FLT synthesis and the time elapsed until patient injection.
The specific activity at the time of patient injection had an
average value (N = 20) of 0.96 Ci/μmol with a range of
0.12 to 1.6 Ci/μmol. The dose of FLT injected was 0.61 to
8.9 μg (for a 0.07 mCi/Kg radiotracer dose). Each 18F-FLT
dose passed rigorous radiochemical and chemical purity
assays and pyrogenicity and sterility testing. All doses
administered contained less than 10% (v/v) ethanol
(USP) in no more than a 10 mL solution of isotonic
saline.
PET imaging protocol
All PET studies were performed on a General Electric PET
Advance Tomograph (General Electric Medical Systems)
using methods described previously [11,15]. All 18F-FLT
doses were calculated based on patient weight (2.59 MBq/
Kg (0.07 mCi/Kg)) with a maximal dose of 185 MBq (5
mCi).  18F-FLT was administered intravenously over 1
minute using an infusion pump. A 1.5 or a 2-hour long
dynamic acquisition was performed as previouslyBMC Nuclear Medicine 2007, 7:3 http://www.biomedcentral.com/1471-2385/7/3
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described [15]. Dynamic PET acquisition was accompa-
nied by arterial or venous serial blood sampling. For eight
patients imaged over 120 minutes, 24 arterial blood sam-
ples were collected as follows: every 20 seconds for the
first 3 minutes, every 30 seconds for the next minute,
every minute for the next 4 minutes, every 2 minutes for
the next 2 minutes, every 5 minutes for the next 10 min-
utes, every 10 minutes for the next 40 minutes, and at 90
and 110 minutes after injection. For the remaining 12
patients, 8–9 serial venous blood samples were collected
at the following times: 1, 2, 5, 10, 20, 40, 60, and 90 min-
utes for a 90-minute acquisition and at an additional 110
minute time point for a 120-minute acquisition.
Toxicology testing
Potential changes in the hepatic, hematological or renal
function of subjects resulting from administration of 18F-
FLT were explored with standard blood laboratory assays.
These tests were initially performed within a mean of 5.4
days before 18F-FLT injection as well as just after the PET
imaging procedure (mean 2 hours 20 minutes post-injec-
tion) (Table 1). The clinical Laboratory Medicine facilities
at the University of Washington Medical Center or the
Veterans Affairs Puget Sound Health Care System per-
formed these analyses. Subsequent laboratory evaluations
acquired as part of the patients' routine care were also
reviewed and compared to those obtained earlier. These
additional laboratory values fall into one of the following
three categories: 1) 5–24 hours, 2) 1–7 days, or 3) greater
than 1 week after the 18F-FLT study. Therefore, each
patient's blood samples were analyzed: before the PET
study, immediately after the PET study, and for at least
one of the other three categories listed above (Table 1).
The following blood assays were performed: 1) sodium,
potassium, chloride, and glucose levels, 2) hepatic func-
tion assays (aspartate aminotransferase (AST or SGOT),
alanine aminotransferase (ALT or SGPT), albumin, alka-
line phosphatase (Alk Phos), and total bilirubin); 3) cre-
atinine and blood urea nitrogen (BUN); 4) hematologic
evaluation consisting of a complete blood count includ-
ing red blood cell count (RBC), hematocrit, hemoglobin,
white blood cell count (WBC) and platelet count. An
interim statistical analysis carried out on the first 17
patient data sets demonstrated a significant lowering
trend for the red blood cell count and hematocrit when
comparing values measured before 18F-FLT injection to
values obtained just at the end of 18F-FLT imaging. There-
fore, a measure of haptoglobin level was added for the last
three patients to assess for the presence of hemolysis.
In addition, each patient underwent a standard neurolog-
ical examination performed by a neurologist or an
internist before and immediately after 18F-FLT PET imag-
ing. The evaluation included but was not limited to a Fol-
stein mini mental status examination, as well as
evaluations of cranial nerve responses, motor strength,
hand strength, muscle bulk and tone, sensation to light
and touch, deep tendon reflexes, cognitive testing, Romb-
erg testing, and gait testing. Patients' clinical records for
the four months following 18F-FLT PET imaging were also
reviewed looking for evidence of new neuropathy or neu-
rological deficit.
From the dynamic PET acquisition data, blood time-activ-
ity curves were generated for each patient using regions-
of-interest of at least 16 pixels (surface 2.89 cm2) placed
in the center of the left ventricular chamber of the heart on
each of three adjacent imaging planes [15,18]. Each data-
set was corrected for image duration, injected dose, 18F
decay, and PET scanner efficiency. The area under the
curve (AUC) was calculated for each blood time-activity
curve (TAC) for the duration of imaging (90 or 120 min-
utes) and scaled for a standard 5 mCi 18F-FLT injection.
With a specific activity greater than 0.1 Ci/μmol, 5 mCi of
18F-FLT represents a maximum dose of 12.2 μg of FLT
injected.
Flexner et al. reported FLT dosing regimens in patients as
an area under the blood FLT concentration curve over 12
hours (AUC12), since their patients were dosed at 12-hour
intervals. Hence, in order to compare our data with
Flexner's, we performed an exponential polynomial curve
fit (TableCurve 2D, SYSTAT Software Inc.) of the TACs
allowing subsequent time integration to be carried out to
12 hours. This approach provided a PET imaging-derived
AUC12 for each patient blood TAC.
A separate estimation of the AUC12 was calculated from
the blood samples collected during PET data acquisition.
These samples were counted for radioactivity and decay-
corrected according to a method previously described
[13]. The resulting blood TACs were also scaled for a
standard 5 mCi 18F-FLT injection. Curve fitting and inte-
gration over 12 hours yielded a blood-derived AUC12
value for each patient.
Statistical analysis
Laboratory test values were first confirmed for normality
using the k-s distance test for each type of clinical labora-
tory result. Subsequently, parametric tests were used con-
sisting of a one-way Anova test for repeat sampling and a
Bonferroni post-test. Comparison between the two meth-
ods to calculate AUC12 was performed using a Wilcoxon
signed rank test. The statistical software packages SPSS
(Statistical Package for the Social Sciences, SPSS Inc.) and
PRISM (Prism v.4, GraphPad Software) were utilized for
this purpose.BMC Nuclear Medicine 2007, 7:3 http://www.biomedcentral.com/1471-2385/7/3
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Results
Laboratory assays
Different laboratory values monitored for this study are
plotted with respect to the time categories for each of the
20 study participants (Figures 1 and 2). Table 2 summa-
rizes the mean and standard deviation for each parameter
over time. No statistically significant change was observed
in sodium, potassium, chloride, glucose, creatinine, BUN,
SGOT, SGPT, Alk Phos, total bilirubin, WBC, and platelet
levels (p > 0.05). The mean for each of these parameters
remained within normal limits over time (Table 2). Albu-
min, RBC, and hematocrit show a statistically significant
decrease over time. Bonferroni analyses demonstrated
that albumin decrease results mainly from an initial
decrease of 11.5% between the pre-18F-FLT PET measure
and the immediate post-18F-FLT PET blood draw (p  <
0.001). However, mean albumin values stayed within
normal limits. For RBC and hematocrit (as well as for
hemoglobin level, not plotted), significant decreases of
respectively 4.7% and 4.5% occur between pre-18F-FLT
and immediate post-18F-FLT blood drawn (p < 0.001), fol-
lowed by decreases of respectively 8.3% and 8.4%
between 5–24 hours and 1–7 days (p < 0.001). However,
average levels for RBC remained within normal limits for
the 1–7 days time point. Average values were just below
normal for RBC after 1 week and for hematocrit for the
first week and onwards. Because they are the only labora-
tory parameters to exhibit a change, raw data, mean and
standard deviations (SD) for albumin, RBC, and hemat-
ocrit are also plotted for illustration (Figures 1F, 2A, 2C).
The effect of surgical intervention on hemoglobin, hema-
tocrit and RBC values was assessed by re-analyzing the
data after excluding all post-surgical lab values from the
original dataset. Bonferroni post-test performed on this
reduced dataset still demonstrates the same significant
decrease in hemoglobin, hematocrit and RBC values from
pre-18F-FLT to immediately post-18F-FLT times but with-
out subsequent lowering at later time points. Haptoglobin
levels measured for the last 3 patients of the study did not
reveal any evidence of hemolysis.
No side effects including nausea, vomiting, dizziness, or
headache were reported during 18F-FLT injection or dur-
ing the following 2.0–2.5 hours.
Neurological evaluations
No change was observed in the results of the neurological
examinations performed on all patients before and imme-
diately after the 18F-FLT PET imaging sessions. A review of
each subject's clinical record covering the 4 months fol-
lowing 18F-FLT PET imaging revealed no interval develop-
ment of new neurological complaints, signs or symptoms
by the study participants. In particular, no new peripheral
neuropathy was reported in any of the 20 patients.
Calculation of AUC12 for a 5 mCi radiotracer dose of 18F-
FLT
Figure 3 depicts 4 blood-derived TACs, each normalized
to a standard 5 mCi 18F-FLT injected dose. These decay-
corrected curves illustrate the variability observed across
patients in the elimination of 18F-FLT from blood. They
also illustrate the observation that at the conclusion of
imaging the quantity of residual 18F-FLT in the blood was
small in all 20 patients. At 90 minutes post-18F-FLT injec-
tion, the concentration of decay-corrected activity is on
average 0.0454 ± 0.0272 μCi/mL. With a lowest accepta-
ble specific activity of 0.1 Ci/μmol, this corresponds to a
concentration of FLT of 0.111 ± 0.0665 ng/mL if all radi-
oactivity is assumed to be in the form of 18F-FLT (FLT has
a molecular weight of 244 g). Therefore, for the purpose
of this study we are not considering the main labeled
metabolite of FLT, 18F-FLT-glucuronide, separately from
18F-FLT.
The imaging-derived AUC12  values range from 0.405
ng*h/mL to 1.26 ng*h/mL with a mean of 0.770 ± 0.285
ng*h/mL. The calculated blood sample-derived AUC12
ranged from 0.232 ng*h/mL to 1.34 ng*h/mL with a
mean of 0.802 ± 0.303 ng*h/mL. No significant difference
in the AUC12 values obtained by the 2 different methods
was found (Wilcoxon signed rank test, p = 0.66, Figure 4).
Discussion
The purpose of this study was to evaluate the potential
toxicity of 18F-FLT when administered in a radiotracer
dose for PET imaging. Such a study was made necessary
because of previously reported toxicity in clinical trials
employing therapeutic doses. In 1994, Flexner et al. pub-
lished a concentration-control trial involving initially 14
Table 1: Time table
N Minimum Maximum Mean ± SD
Pre-FLT 20 -3 h 43 m -37 d -5.4 d ± 8.7 d
Immediate <5 h 18 1 h 24 m 4 h 12 m 2 h 20 ± 41 m
5 – 24 Hours 18 5 h 37 m 21 h 24 m 9 h 43 ± 5 h 42
First Week 18 1.1 d 6.0 d 4.4 d ± 1.1 d
> 1 week 19 7.4 d 155.8 d 29.3 d ± 39.8 d
m = minutes, h = hours, d = daysBMC Nuclear Medicine 2007, 7:3 http://www.biomedcentral.com/1471-2385/7/3
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asymptomatic HIV-positive patients treated with FLT over
a period of 16 weeks. These patients received a de-escalat-
ing oral dose of FLT starting from 0.125 mg/Kg (AUC12 ~
417 ng*h/mL) every 12 hours to reach a target area under
the curve of 300 ng*h/mL for a 12 hour dosing interval
[17]. Serious grade III hematologic toxicity (anemia and
leukopenia) was observed with concentrations greater
than 300 ng*h/mL. Grade II+ anemia was observed
within 4 weeks with a concentration of 300 ng*h/mL.
Subsequently, a randomized, double-blind phase I/II trial
was designed to characterize FLT pharmacokinetics, anti-
viral activity, and toxicity. Forty-eight patients were rand-
omized into 3 groups with different target areas of FLT
concentration (50 ng*h/mL, 100 ng*h/mL, or 200 ng*h/
mL) for up to 16 weeks of treatment. Grade II+ anemia
developed at doses greater than 100 ng*h/mL, granulocy-
topenia at doses greater than 200 ng*h/mL, and mild
peripheral neuropathy within 40 days at any dose. The
bone marrow toxicity was reversible when the drug was
discontinued. This type of toxicity was not seen with
reduced FLT doses. However, this phase I/II trial was sus-
pended because two patients died from acute hepatic fail-
ure after 12 weeks of therapy, one in Flexner's study at
AUC12 of 200 ng*h/mL, the other from a European trial
using a 10 mg/day regimen. Therefore, the FLT toxicology
data reported for human therapeutic use shows the lowest
toxicity regimen tested to be 50 ng*h/mL for a 12 hour
dosing interval which led to only mild peripheral neurop-
athy within a mean of 40 days of therapy [17]. Therefore,
in addition to discussing our toxicology data for a single
radiotracer dose of 18F-FLT, we will compare this dose
level to the multiple larger doses used in this lowest toxic-
ity clinical regimen.
We evaluated the toxicity of 18F-FLT in a series of 20
patients who underwent 18F-FLT PET imaging. We took
two different approaches to this evaluation: first, a direct
laboratory measure of electrolytes, hepatic, metabolic,
and renal function of these patients; second, a compari-
son of the maximal amount of FLT compound injected for
a 18F-FLT PET study to the therapeutic dose shown to be
the least toxic in clinical trials. To this end, AUC12 values
for our study patients were calculated from both imaging-
derived TACs and actual blood samples.
No change was found in the renal function (BUN and cre-
atinine levels) of the 20 patients studied or in the follow-
ing hepatic function measures: AST, ALT, alkaline
phosphatase, and total bilirubin. As described in the
results section, decreases in the patients' average hemat-
ocrit, RBC and hemoglobin levels were observed. One of
the challenges of this study is that it was designed as a
companion analysis to a primary imaging study per-
formed in potentially resectable NSCLC. As a result, sev-
enteen of 20 (85%) patients studied underwent surgical
staging (mediastinoscopy and/or video assisted thoracos-
copy) with 14/20 also undergoing a tumor resection pro-
cedure, at the same time as the mediastinoscopy, under
general anaesthesia after 18F-FLT PET. Thirteen of the 14
(93%) had resection within 1 week of the 18F-FLT PET
study, 7 of these were the day after the 18F-FLT PET study.
Because surgery involves blood loss and metabolic stress,
hematological values were consequently affected and a
long-term relationship between the 18F-FLT PET study and
hematological values is difficult to establish. Nonetheless,
when we only consider pre-surgical lab values and all lab
values for patients who did not undergo any surgical pro-
cedure, analysis of the data reveals a single small early
drop in hemoglobin, hematocrit and RBC. This suggests
that the additional drop observed in these parameters at
later time points for the whole population is due to surgi-
cal blood loss. The initial decrease in hemoglobin, hema-
Table 2: Laboratory values (mean ± SD) of the 20 patients at each time point and corresponding one-way Anova P values across all 
time points.
Pre-FLT Immediate <5 h 5 – 24 Hours 1 – 7 days > 1 week P
Sodium (mEq/L ± SD) 139.4 ± 1.5 138.2 ± 2.1 138.3 ± 2.0 137.5 ± 1.8 138.1 ± 2.3 0.064
Potassium (mEq/L ± SD) 4.2 ± 0.5 4.2 ± 0.4 4.1 ± 0.4 4.2 ± 0.3 4.2 ± 0.4 0.968
Chloride (mEq/L ± SD) 102.3 ± 3.3 104.2 ± 3.7 104 ± 3.8 102.3 ± 2.4 101.2 ± 3.1 0.055
Glucose (mg/dL ± SD) 95.1 ± 14.8 96.6 ± 20.7 98.5 ± 23.1 105.4 ± 17.7 109.5 ± 14.6 0.175
Creatinine (mg/dL ± SD) 0.885 ± 0.198 0.882 ± 0.207 0.881 ± 0.180 0.910 ± 0.190 0.844 ± 0.217 0.949
BUN (mg/dL ± SD) 15.8 ± 5.0 15.1 ± 5.6 15.2 ± 6.3 14.3 ± 5.2 15.3 ± 5.7 0.959
SGOT (U/L ± SD) 20.8 ± 5.0 22.0 ± 5.1 22.0 ± 5.3 22.2 ± 11.4 21.8 ± 6.7 0.973
SGPT (U/L ± SD) 18.7 ± 6.7 18.5 ± 6.6 19.1 ± 6.5 17.6 ± 5.3 17.2 ± 6.5 0.978
Albumin (g/dL ± SD) 3.9 ± 0.5 3.5 ± 0.4 3.44 ± 0.3 3.1 ± 0.6 3.2 ± 0.8 0.003
Alk Phos (U/L ± SD) 73.8 ± 19.4 61.1 ± 14.7 58.3 ± 17.0 59.5 ± 22.7 0.081
Bilirubin (mg/dL ± SD) 0.647 ± 0.181 0.573 ± 0.246 0.581 ± 0.263 0.621 ± 0.286 0.752 ± 0.418 0.714
RBC (x106/μL ± SD) 4.5 ± 0.4 4.3 ± 0.5 4.2 ± 0.5 3.8 ± 0.3 3.7 ± 0.4 <0.0001
Hematocrit (% ± SD) 40.9 ± 3.1 39.1 ± 4.4 38.4 ± 4.0 35.2 ± 3.4 35.0 ± 3.4 <0.0001
WBC (x103/μL ± SD) 7.6 ± 2.1 7.7 ± 3.4 7.9 ± 3.3 9.5 ± 2.8 9.0 ± 3.2 0.262
Platelets (x103/μL ± SD) 278.1 ± 96.8 259.1 ± 103.1 255.9 ± 103.0 230.1 ± 76.7 233.5 ± 69.5 0.674BMC Nuclear Medicine 2007, 7:3 http://www.biomedcentral.com/1471-2385/7/3
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tocrit and RBC is probably attributable to a dilution effect
since patients were hydrated with 500 cc of IV normal
saline during the PET scan. Giving more credibility to the
dilution hypothesis, haptoglobin measurements per-
formed on the last 3 patients having demonstrated such a
RBC decrease showed no evidence of hemolysis at the end
of the 18F-FLT PET imaging session. Platelet and white
blood cell counts did not show any statistically significant
differences over time and no immediate effect of dilution.
This is likely because immediately available pools of such
cells exist in the body, helping to maintain their levels
despite hydration. Another important point is that the
patients whose medical records contain laboratory values
for times late after 18F-FLT PET are those that had a more
prolonged post-operative course with more severe altera-
tions expected in their laboratory values.
Statistical testing showed that the patients' albumin level
decreased slightly over time but its level remained within
normal limits. However, Bonferroni post-test analysis
shows that this change arises from the initial decrease
(11.5%) between the pre-18F-FLT PET value and the
immediate post-18F-FLT PET blood draw. This decrease is
also likely explained by the hemodilution.
No change was observed in the results of the neurological
examinations performed before and immediately after the
18F-FLT PET study. Furthermore, a review of the clinical
records for the 4 months following 18F-FLT imaging
revealed no new neurological complaints.
The second approach used to estimate the toxicity of a
radiotracer dose of 18F-FLT is based on a comparison of
the corresponding AUC12 to the AUC12 of the lowest and
least toxic therapeutic regimen (50 ng*h/mL). For a 5 mCi
radiotracer dose of 18F-FLT and the lowest accepted spe-
cific activity of 0.1 Ci/μmol, the imaging-derived AUC12
values ranged from 0.405 to 1.262 ng*h/mL with a mean
Hepatic function Figure 1
Hepatic function. Hepatic function: Alkaline phosphatase (A), total bilirubin (B), SGOT (C), SGPT (D), and albumin (E) levels 
sampled before FLT injection (Pre-FLT), up to 5 hours post-FLT (Immediate <5 h), between 5 and 24 hours (5–24 h), between 
day 1 and 7 (1–7 d) and later than one week (>1 wk) after FLT injection. Lines link all values for an individual patient over time. 
On Figure F (same data as Figure E) the mean +/- standard deviation for albumin is plotted over time. Dotted horizontal lines 
illustrate the upper and lower normal limits (reference range) for each test.BMC Nuclear Medicine 2007, 7:3 http://www.biomedcentral.com/1471-2385/7/3
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of 0.770 ± 0.285 ng*h/mL. This corresponds to 0.81% to
2.52% of the lowest and least toxic clinical trial AUC12 of
50 ng*h/mL. The blood samples-derived AUC12 values
ranged from 0.232 to 1.34 ng*h/mL with a mean of 0.802
± 0.303 ng*h/mL. This corresponds to 0.46% to 2.68% of
the least toxic clinical trial. Therefore, the AUC12 of a sin-
gle 5 mCi radiotracer dose of 18F-FLT is very small com-
pared to the AUC12 of the least toxic therapeutic trial. In
addition, one should realize that the latter trial adminis-
tered FLT every 12 hours for 112 days with the only toxic-
ity, peripheral neuropathy, developing at a mean of 40
days. A conservative comparison of a radiotracer dose of
18F-FLT to 80 therapeutic doses of FLT shows that 5 mCi
of FLT represents at most 2.68%/80 or nearly 3,000 times
less FLT administered than in Flexner's least toxic regi-
men, a considerable difference. Therefore, this provides
further justification of the expected negligible toxicity
from 5 mCi of 18F-FLT for PET imaging. Alterations in
white blood cell count reported by Flexner et al at higher
AUC12 regimens were not observed in our patients. Fur-
thermore, by radiochemistry requirements, the lowest
acceptable specific activity for 18F-FLT at the end of synthe-
sis is 0.1 Ci/μmol. For a maximal injected dose of 5 mCi,
this would correspond to a maximum unlabeled drug
dose of 12.2 μg of FLT. Using the correspondence between
a 0.125 mg/Kg dose and an AUC12 of 417 ng*hr/mL
reported by Flexner [17], the least toxic dose of 50 ng*hr/
mL corresponds to a dose of 0.015 mg/Kg, or 1.05 mg
every 12 hours for a 70 Kg person. Over 40 days (80
doses), this is 1.05 mg × 80 doses or a 6,885-fold greater
dose than that involved in a radiotracer administration of
[18F]FLT. In practice, the typical specific activity levels
were 3 to 4 times higher than the acceptable level of 0.1
Ci/μmol. This implies that for a 5 mCi 18F-FLT dose, even
smaller amounts of FLT are injected.
Conclusion
This study shows no evidence of toxicity or complication
attributable to a 0.07 mCi/Kg (max 5 mCi) dose of 18F-FLT
intravenously injected in the 20 patients studied. In addi-
tion, we provided careful estimation of the relative
amount of FLT involved in a 5 mCi radiotracer dose for
comparison to that administered in previously reported
clinical trials. We believe that the use of such a radiotracer
dose of 18F-FLT for PET imaging in human subjects is safe.
Hematologic function Figure 2
Hematologic function. Hematologic function: Red blood cells (A), white blood cells (B), hematocrit (C) levels sampled 
before FLT injection (Pre-FLT), up to 5 hours post-FLT (Immediate <5 h), between 5 and 24 hours (5–24 h), between day 1 
and 7 (1–7 d) and later than one week (>1 wk) after FLT injection. Lines link all values for an individual patient over time. On 
Figures A & C the means +/- standard deviations for red blood cells (A) and hematocrit (C) are plotted over time. Dotted hor-
izontal lines illustrate the upper and lower normal limits (reference range) for each test.
Examples of TACs Figure 3
Examples of TACs. Blood-derived time-activity curves 
(TACs) of 4 patients undergoing 18F-FLT PET.BMC Nuclear Medicine 2007, 7:3 http://www.biomedcentral.com/1471-2385/7/3
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Since 18F-FLT dosimetry is also known [15], widespread
clinical PET imaging with 18F-FLT can now be undertaken.
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